Sun Pharmaceutical Industries Q2 FY27 Results: Consolidated Net Profit ₹1,995 Crore on Total Income of ₹16,716 Crore
Earnings
pharmaceuticals
Blacklitt Research4 min read
Steve Buissinne (stevepb), via Wikimedia Commons (CC0). Illustrative image.
Sun Pharmaceutical Industries reported consolidated total income of ₹16,716.03 crore and net profit of ₹1,995.07 crore for the quarter ended 30 Sep 2026. On a standalone basis, total income was ₹6,222.93 crore and net profit ₹871.29 crore. The company said in a filing on 30 Oct 2026.
Key highlights
Consolidated
Including its subsidiaries
Total income: ₹16,716.03 crore, up 11.8% YoY and 4.3% QoQ
Net profit and EPS: ₹1,995.07 crore, down 36.2% YoY; basic EPS ₹8.30 against ₹13.00 a year earlier
Exceptional items: ₹346.16 crore of Organon-related acquisition costs and a ₹922.67 crore settlement charge, with a ₹95.34 crore tax benefit
Revenue from operations: ₹16,198.71 crore, up 11.9% YoY
Standalone
The company on its own, without its subsidiaries
Total income: ₹6,222.93 crore, up 34.7% YoY and 5.8% QoQ
Net profit and EPS: ₹871.29 crore, up 54.4% YoY; basic EPS ₹3.60 against ₹2.40 a year earlier
Tax expense: ₹331.70 crore against ₹107.53 crore a year earlier, up 208.5%
Summary
Consolidated ₹ crore
Particulars
Q2 FY27
Q2 FY26
YoY
Q1 FY27
QoQ
16,716.03
14,948.23
+11.8%
16,023.50
+4.3%
Revenue from operations
16,198.71
14,478.31
+11.9%
15,299.88
+5.9%
Other income
517.32
469.92
+10.1%
723.62
-28.5%
1,995.07
3,124.95
-36.2%
2,901.23
-31.2%
Profit before tax
3,159.37
4,167.61
-24.2%
4,098.81
-22.9%
Finance costs
74.67
99.86
-25.2%
99.67
-25.1%
Depreciation
758.34
729.50
+4.0%
738.72
+2.7%
Tax expense
1,157.79
1,030.52
+12.4%
1,188.01
-2.5%
Net profit margin
11.94%
20.91%
-8.97 pp
18.11%
-6.17 pp
EPS, basic (₹)
8.30
13.00
-36.2%
12.10
-31.4%
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Consolidated total income rose 11.8% year on year to ₹16,716.03 crore, but net profit fell 36.2% to ₹1,995.07 crore, a larger fall than the 24.2% decline in profit before tax to ₹3,159.37 crore. The statement carries exceptional items of ₹346.16 crore for acquisition-related costs on the agreement to acquire Organon & Co., and a ₹922.67 crore charge for a settlement in the In re Generic Pharmaceuticals Pricing Antitrust Litigation, which the filing says is inclusive of legal cost. A tax benefit of ₹95.34 crore is recorded against the settlement charge.
Revenue from operations rose 11.9% to ₹16,198.71 crore, faster than other income, which rose 10.1% to ₹517.32 crore. Other income is 3.1% of total income and 16.4% of profit before tax this quarter. Finance costs of ₹74.67 crore are 0.4% of total income, and depreciation rose 4.0% to ₹758.34 crore.
Against the June quarter, total income rose 4.3% and net profit fell 31.2% from ₹2,901.23 crore. Tax expense of ₹1,157.79 crore is 36.6% of profit before tax of ₹3,159.37 crore, and basic EPS of ₹8.30 compares with ₹12.10 in the June quarter and ₹13.00 a year earlier.
Standalone ₹ crore
Particulars
Q2 FY27
Q2 FY26
YoY
Q1 FY27
QoQ
6,222.93
4,620.90
+34.7%
5,881.30
+5.8%
Revenue from operations
6,141.92
4,548.11
+35.0%
5,741.13
+7.0%
Other income
81.01
72.79
+11.3%
140.17
-42.2%
871.29
564.22
+54.4%
1,115.14
-21.9%
Profit before tax
1,202.99
671.75
+79.1%
1,486.45
-19.1%
Finance costs
276.96
248.33
+11.5%
278.48
-0.5%
Depreciation
315.79
336.30
-6.1%
307.92
+2.6%
Tax expense
331.70
107.53
+208.5%
371.31
-10.7%
Net profit margin
14.00%
12.21%
+1.79 pp
18.96%
-4.96 pp
EPS, basic (₹)
3.60
2.40
+50.0%
4.60
-21.7%
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Standalone net profit rose 54.4% to ₹871.29 crore, slower than profit before tax, which rose 79.1% to ₹1,202.99 crore. Total income rose 34.7% year on year to ₹6,222.93 crore.
Standalone revenue from operations rose 35.0% to ₹6,141.92 crore, faster than other income, which rose 11.3% to ₹81.01 crore. Other income is 1.3% of total income and 6.7% of profit before tax. Finance costs of ₹276.96 crore are 4.5% of total income, and depreciation fell 6.1% to ₹315.79 crore.
Tax expense rose to ₹331.70 crore from ₹107.53 crore a year earlier, up 208.5%, and is 27.6% of profit before tax. Against the June quarter, standalone net profit fell 21.9% from ₹1,115.14 crore while total income rose 5.8%. Basic EPS of ₹3.60 compares with ₹2.40 a year earlier and ₹4.60 in the June quarter.
The filing says the company signed a definitive agreement on 27 Apr 2026 to acquire all outstanding shares of Organon & Co. for cash of USD 14.00 per share, on an enterprise valuation of USD 11.75 billion. Organon shareholders approved the deal on 23 Jul 2026, approvals have been received for most filings, and the indicative closing is Q4FY27.
The company acquired 100% of Innovcare Lifesciences Private Limited for ₹271.19 crore in the quarter, and the filing says results for the quarter and half year are not comparable with other periods presented. From FY 2026-27 the company opted for the concessional tax regime under Section 115BAA at an effective rate of 25.168%, in place of the regular rate of 34.944%.
India Formulations sales rose 17.3% to ₹5,552.30 crore, and the company says its market share rose to 8.6% from 8.3%. US Formulations sales were US$ 455 million, a decline of 8.2%; the filing cites lenalidomide erosion impact and says US sales were slightly up excluding lenalidomide for the quarter. Ilumya is now approved in the US for adults with active psoriatic arthritis.
Inference
The earnings presentation says the company successfully allotted its debut non-convertible debentures of ₹7,816 crore and reports a net cash position of US$ 3.3 billion.
The Board meeting was temporarily adjourned at the time of the announcement, and the outcome of the remaining agenda items will be submitted upon conclusion of the meeting.
What the filing leaves open is the total cost of the Organon acquisition, the adjustments from reported net profit to the adjusted net profit of ₹3,162.00 crore, and the closing date beyond the indicative Q4FY27 timeline.
Create a free account to read the rest of this article and the analysis that follows.
By continuing you agree to our Terms and Privacy Policy, and to receive updates from Blacklitt by email. You can unsubscribe anytime.
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
SUNPHARMASun Pharmaceutical Industries Ltd.
